Zydus receives USFDA approval for Norepinephrine Bitartrate Injection

24 Jul 2022 , 01:33 AM

Zydus Lifesciences has received final approval from the United States Food and Drug Administration USFDA to market Norepinephrine Bitartrate Injection USP4 mg4 mL 1 mgmL Single-Dose Vial USRLD Levophed Norepinephrine Bitartrate is indicated for restoration of blood pressure in adult patients with acute hypotensive state The drug will be manufactured at the groups topical injectable manufacturing facility at Jarod India Norepinephrine Bitartrate Injection USP 1mg1 mL had annual sales of US$ 638 million in the United States according to IQVIA data IQVIA MAT May 2022